Acute Myocardial Infarction and Unstable Angina Patients With PCSK9 Inhibitor Usage Study
Overview
- Phase
- Not Applicable
- Intervention
- PCSK9 inhibitor
- Conditions
- Lipid Metabolism
- Sponsor
- Shenzhen People's Hospital
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- cardiovascular prognosis
- Last Updated
- 3 years ago
Overview
Brief Summary
Acute coronary syndrome (ACS) is a lethal disease, reduced low-density lipoprotein (LDL) cholesterol due to inhibition of proprotein convertase subtilisin/kexin 9 (PCSK9) reduces cardiovascular events and improve cardiovascular prognosis. we assuming that PCSK9 inhibitor could bring metabolic change in serum, in order to investigate the metabolic modification, we conduct this clinical trial.
Investigators
Ying Li
professor
Shenzhen People's Hospital
Eligibility Criteria
Inclusion Criteria
- •New diagnosis ACS patient by serum biomarker and coronary arteriography.
Exclusion Criteria
- •Severe renal dysfunction acute or chronic bacterial and viral infections sleep apnea cancer
Arms & Interventions
pcsk9 inhibitor group
patients with severe coronary stenosis diagnosed ACS. The baseline blood and urine would be collected, thereafter, the PCSK9 inhibitor would be injected. 64-72 hours after, the blood and urine sample collection would be performed.
Intervention: PCSK9 inhibitor
Outcomes
Primary Outcomes
cardiovascular prognosis
Time Frame: 52 weeks
composite outcome of time to first occurrence of cardiovascular death, myocardial infarction, unstable angina and heart failure.